LYCOS RETRIEVER 
Trial: Phase Ii
built 389 days ago
Pure form of creatine is being provided by Avicena Group for phase III trial. Trial enrollment to begin in March 2007. In December 2006, the company announced it had signed an agreement with the National Institute of Neurological Disorders and Stroke to supply PD-02 for a Phase III trial that is being planned by the Institute. "The trial is to be led by Karl Kieburtz, of the University of Rochester in New York, and Barbara C. Tilley, Ph.D., of the Medical University of South Carolina in Charleston. The trial is designed to evaluate PD-02's potential to slow the progression of Parkinson's disease." (Medical News Today) Sponsor filed a "composition of matter patent application" with the United States Patent and Trademark Office in April 2007 to "cover potential treatments for Parkinson's disease, a progressive neurodegenerative disease."
Source:
"The addition of the Lahey Clinic to the Phase II trial of Atiprimod in advanced carcinoid patients signifies our continuing commitment to facilitate rapid enrollment of this trial," said Dr. Gary S. Jacob, Chief Executive Officer of Callisto. "The Lahey Clinic specializes in the treatment of neuroendocrine cancers, and has built a significant reputation within the carcinoid community, which should substantially enhance the pace of enrollment and increased accessibility to prospective patients interested in participating in this trial."
Source:
"This trial is the culmination of nine years of research suggesting the potency of CD34+ cells for treating heart disease," said Dr. Losordo. "We are delighted that we are on the threshold of the next important phase of testing for this unique autologous stem cell therapy."
Source:
MORE ABOUT
Phase Ii